Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries

Abstract

We examined real-world data on management of relapsed/refractory Hodgkin lymphoma (R/R HL) in five European countries and the consistency of these data with guideline recommendations. Retrospective clinical and epidemiologic data for 509 patients with R/R HL treated between January 2014 and March 2015 were collected at centers in France, Germany, Italy, Spain, and the United Kingdom. Mean age was 46.3 years; 73.3% were receiving second-line therapy for a first relapse during the reporting period. Most patients received ABVD as front-line chemotherapy, except in Germany where escalated BEACOPP was used more often. The proportion of patients receiving stem cell transplantation (SCT) was 44%; 85% of transplants occurred at first relapse. Brentuximab vedotin (BV) was usually administered after autologous SCT, and was initiated for 65% of patients following SCT failure. Our findings suggest that R/R HL management across these countries is broadly consistent with guideline recommendations and that BV is well-integrated into treatment pathways.

Keywords:

• Brentuximab vedotin
• CD30
• Europe
• Hodgkin lymphoma
• real-world data
• autologous stem cell transplantation

Acknowledgments

Dr Collins acknowledges support from the Blood Theme of the Oxford Biomedical Research Centre. Data collection, monitoring, and analysis were provided by Philippa Wilson-Browne and Lenka Kellerman at OncologyInformationService, Freiburg, Germany. Ian Faulkner of Ogilvy 4D, Oxford, UK provided writing support with funding from Takeda Pharmaceuticals. Takeda provided a review of the outline and manuscript drafts and comments were incorporated if deemed appropriate by the authors.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2017.1421762.